Results 51 to 60 of about 7,686 (201)

Cardiovascular risk and dyslipidemia among persons living with HIV: A review [PDF]

, 2017
Background: Aim of this review is to focus the attention on people living with HIV infection at risk of developing a cardiovascular event. What is or what would be the most suitable antiretroviral therapy Which statin or fibrate to reduce the risk How to
Cicalini, S, D'Abbraccio, M, d'Ettorre, G, Di Biagio, A, Maggi, P, Martinelli, C, Nunnari, G, Rusconi, S, Sighinolfi, L, Spagnuolo, V, Squillace, N   +10 more
core   +3 more sources

Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

Cardiovascular Diabetology, 2023
Background Pericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2 diabetes mellitus (T2DM). However, whether the coronary inflammation revealed by this novel index could
Meng-Meng Yu, Xin Zhao, Yin-Yin Chen, Xin-Wei Tao, Jun-Bo Ge, Hang Jin, Meng-Su Zeng   +6 more
doaj   +1 more source

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes [PDF]

, 2016
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease.
Brook, Robert, Catapano, Alberico L., Chapman, John, Davey Smith, George, Fazio, Sergio, Ference, Brian, Giugliano, Robert, Neff, David, Robinson, Jennifer, Sabatine, Marc S, Voros, Szilard   +10 more
core   +3 more sources

Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships

ChemMedChem, Volume 21, Issue 1, January 2026.
Green chemistry‐based late‐stage functionalization (LSF) of the anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) early lead compound 5c led to optimized analogs with improved metabolic stability/PCSK9 IC50 ratio. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key drug target for the treatment of different hypercholesterolemia ...
Lisa Giannessi, Maria Giovanna Lupo, Martina Ugolotti, Bianca Papotti, Beatrice Mattina, Maria Grazia Martina, Anna Demurtas, Cristina Padula, Sara Nicoli, Marco Crescenzio, Nicola Ferri, Francesca Zimetti, Marco Radi   +12 more
wiley   +1 more source

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society [PDF]

, 2014
AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular ...
Averna, M, AVERNA, Maurizio, Boileau, C, Boileau, C, Boren, J, Boren, J, Bruckert, E, Bruckert, E, Catapano, A, Catapano, A, Chapman, M, Chapman, M, Chapman, M, Cuchel, M, Cuchel, M, Defesche, J, Defesche, J, Descamps, O, Descamps, O, Ginsberg, H, Ginsberg, H, Ginsberg, H, Hegele, R, Hegele, R, Hovingh, G, Hovingh, G, Humphries, S, Humphries, S, Kovanen, P, Kovanen, P, Kuivenhoven, J, Kuivenhoven, J, Masana, L, Masana, L, Nordestgaard, B, Nordestgaard, B, Pajukanta, P, Pajukanta, P, Parhofer, K, Parhofer, K, Raal, F, Raal, F, Ray, K, Ray, K, Santos, R, Santos, R, Stalenhoef, A, Stalenhoef, A, Steinhagen Thiessen, E, Steinhagen Thiessen, E, Stroes, E, Stroes, E, Taskinen, M, Taskinen, M, Tybjaerg Hansen, A, Tybjaerg Hansen, A, Watts, G, Watts, G, Wiegman, A, Wiegman, A, Wiklund, O, Wiklund, O.   +61 more
core   +1 more source

Astragalus membranaceus—Salvia miltiorrhiza Decoction Ameliorates Metabolic Syndrome and Gut Microbiota Dysbiosis Induced by High‐Fat Diet: A Comparative Study

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
The optimal pairing ratio of ASDs against hyperlipidemia was systematically investigated. ASD maintains intestinal homeostasis and improves the systemic inflammatory response. A new LC–MS/MS method for the determination of derivatized SCFAs was established. ASD regulates the gut microbiota and its metabolites (SCFAs and BAs).
Haiyin Zhang, Haofang Wan, Yihang Lu, Yu He, Haitong Wan, Chang Li   +5 more
wiley   +1 more source

Genetics of coronary artery disease – A clinician's perspective [PDF]

, 2014
Coronary artery disease (CAD) is the major cause of fatality and disability among all cardiovascular diseases (CVD). Intricate interactions of genes and environment dictate the outcomes of CAD.
Bailes, M., Barr, E. D., Bassa, C. G., Bhandari, S., Bhat, N. D. R., Burgay, M., Burke-Spolaor, S., Cameron, A. D., Champion, D. J., Eatough, R. P., Flynn, C. M. L., Freire, P. C. C., Jameson, A., Johnston, S., Karuppusamy, R., Keith, M. J., Kramer, M., Levin, L., Lorimer, D. R., Lyne, A. G., McLaughlin, M. A., Ng, C., Petroff, E., Possenti, A., Ridolfi, A., Stappers, B. W., Straten, W. van, Tauris, T. M., Tiburzi, C., Wex, N.   +29 more
core   +4 more sources

Reduced Serum Soluble L‐Selectin Levels but Not PCSK9 May Be Associated With Generalized Anxiety Disorder: A Case–Control Study

Journal of Clinical Laboratory Analysis, Volume 40, Issue 1, January 2026.
The study included 88 generalized anxiety disorder (GAD) patients and 88 age and sex‐matched healthy controls (HCs). A psychiatrist confirmed the GAD diagnosis, assessed symptom severity using the GAD‐7 scale, and evaluated controls based on the DSM‐5 criteria.
Farzana Akter Munny, Abir Hasan Pranto, Shimanta Paul, Md. Aminul Haque, Rashna Sharmin, Sharifa Sultana, Md. Alamgir Hossain, Md. Rabiul Islam   +7 more
wiley   +1 more source

Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study

Therapeutic Advances in Cardiovascular Disease
Aims: The HEYMANS study observed patients receiving evolocumab as part of routine clinical hyperlipidemia management. It was designed to capture data on clinical parameters relevant to health authorities and physicians. Methods: This was a European multi-
Isabella Sudano, Stephan Krähenbühl, François Mach, Anne Anstett, Nafeesa Dhalwani, Ian Bridges, Mahendra Sibartie, Kausik K. Ray   +7 more
doaj   +1 more source

Evolocumab Reduces Oxidative Stress and Lipid Peroxidation in Obese Zucker Rats

Pathophysiology
Background/Objectives: Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to low-density lipoprotein (LDL) receptors, thus allowing more LDL receptors to remove LDL cholesterol from the blood.
Martina Cebova, Radoslava Bulkova, Olga Pechanova   +2 more
doaj   +1 more source